西南国防医药
西南國防醫藥
서남국방의약
MEDICAL JOURNAL OF NATIONAL DEFENDING FORCES IN SOUTHWEST CHINA
2014年
8期
845-848
,共4页
带状疱疹%神经痛%神经生长因子%腺苷钴胺%疗效
帶狀皰疹%神經痛%神經生長因子%腺苷鈷胺%療效
대상포진%신경통%신경생장인자%선감고알%료효
herpes zoster%neuralgia%mouse nerve growth factor(mNGF)%cobamamide%curative effect
目的：观察鼠神经生长因子（mNGF）及腺苷钴胺联合用药对带状疱疹急性期神经痛的治疗效果。方法将90例发病5 d 内的带状疱疹患者随机分为3组，每组30例，除予以抗病毒等基础治疗外，腺苷钴胺组肌肉注射腺苷钴胺1.0 mg，1次/ d；mNGF 组肌肉注射鼠神经生长因子30μg，1次/ d；联合组肌肉注射腺苷钴胺1.0 mg ﹢鼠神经生长因子30μg，1次/ d，治疗持续14 d。观察50%疱疹结痂的时间，治疗前、治疗7 d、14 d 后疼痛程度[视觉模拟评分（VAS）评分]以及疼痛缓解的总有效率。结果3组50%疱疹结痂时间是：腺苷钴胺组（9.68±2.20）d，mNGF 组（9.40±1.95）d，联合组（9.17±2.30）d，均无明显差异（P ﹥0.05）；3组 VAS评分在治疗后较治疗前均降低，其中腺苷钴胺组与 mNGF 组治疗后 VAS 评分无显著差异，但联合组治疗后 VAS 评分明显低于其他两组（P ﹤0.05）；治疗总有效率腺苷钴胺组、mNGF 组和联合组分别是63.33%、66.67%、90.00%，联合组更优（P ﹤0.05）。结论mNGF 联合腺苷钴胺治疗带状疱疹急性期神经痛效果显著，优于单独应用一种药物。
目的：觀察鼠神經生長因子（mNGF）及腺苷鈷胺聯閤用藥對帶狀皰疹急性期神經痛的治療效果。方法將90例髮病5 d 內的帶狀皰疹患者隨機分為3組，每組30例，除予以抗病毒等基礎治療外，腺苷鈷胺組肌肉註射腺苷鈷胺1.0 mg，1次/ d；mNGF 組肌肉註射鼠神經生長因子30μg，1次/ d；聯閤組肌肉註射腺苷鈷胺1.0 mg ﹢鼠神經生長因子30μg，1次/ d，治療持續14 d。觀察50%皰疹結痂的時間，治療前、治療7 d、14 d 後疼痛程度[視覺模擬評分（VAS）評分]以及疼痛緩解的總有效率。結果3組50%皰疹結痂時間是：腺苷鈷胺組（9.68±2.20）d，mNGF 組（9.40±1.95）d，聯閤組（9.17±2.30）d，均無明顯差異（P ﹥0.05）；3組 VAS評分在治療後較治療前均降低，其中腺苷鈷胺組與 mNGF 組治療後 VAS 評分無顯著差異，但聯閤組治療後 VAS 評分明顯低于其他兩組（P ﹤0.05）；治療總有效率腺苷鈷胺組、mNGF 組和聯閤組分彆是63.33%、66.67%、90.00%，聯閤組更優（P ﹤0.05）。結論mNGF 聯閤腺苷鈷胺治療帶狀皰疹急性期神經痛效果顯著，優于單獨應用一種藥物。
목적：관찰서신경생장인자（mNGF）급선감고알연합용약대대상포진급성기신경통적치료효과。방법장90례발병5 d 내적대상포진환자수궤분위3조，매조30례，제여이항병독등기출치료외，선감고알조기육주사선감고알1.0 mg，1차/ d；mNGF 조기육주사서신경생장인자30μg，1차/ d；연합조기육주사선감고알1.0 mg ﹢서신경생장인자30μg，1차/ d，치료지속14 d。관찰50%포진결가적시간，치료전、치료7 d、14 d 후동통정도[시각모의평분（VAS）평분]이급동통완해적총유효솔。결과3조50%포진결가시간시：선감고알조（9.68±2.20）d，mNGF 조（9.40±1.95）d，연합조（9.17±2.30）d，균무명현차이（P ﹥0.05）；3조 VAS평분재치료후교치료전균강저，기중선감고알조여 mNGF 조치료후 VAS 평분무현저차이，단연합조치료후 VAS 평분명현저우기타량조（P ﹤0.05）；치료총유효솔선감고알조、mNGF 조화연합조분별시63.33%、66.67%、90.00%，연합조경우（P ﹤0.05）。결론mNGF 연합선감고알치료대상포진급성기신경통효과현저，우우단독응용일충약물。
Objective To observe the effects of mouse nerve growth factor(mNGF)combined with cobamamide on neuralgia of acute herpes zoster. Methods 90 cases of herpes zoster patients with onset time ﹤ 5 days were randomly divided into 3 groups:cobamamide group,mNGF group and combined group,30 cases in each;antiviral therapy was performed on all the patients in the 3 groups,while injection of cobamaide(1. 0 mg),once a day,was added to patients in cobamamide group,injection of mNGF(30 μg), once a day,to patients in mNGF group and combined injection of cobamamide(1. 0 mg)and mNGF(30 μg),once a day,to patients in combined group,the courses in the 3 groups all lasted for 14 days;an observation was made to the crusting time of 50% lesion,visual analog scales(VAS)at the time point of before treatment,the 7th day and the 14th day after treatment,and the total effective rate of pain relief. Results The crusting time of 50% lesion was(9. 68 ± 2. 20)days in cobamamide group,(9. 40 ± 1. 95)days in mNGF group and(9. 17 ± 2. 30)days in combined group,the difference among the 3 groups was not obvious(P ﹥ 0. 05);VAS in the 3 groups all decreased after treatment,no significant difference was found between cobamamide group and mNGF group after treatment,while VAS in combined group after treatment was much lower than those in the other 2 groups(P ﹤ 0. 05);the total effective rate was 63. 33% in cobamamide group,66. 67% in mNGF group and 90. 00% in combined group,and the total effective rate in combined group was the most superior(P ﹤ 0. 05). Conclusions The effect of combined application of mNGF and cobamamide on neuralgia of acute herpes zoster is much better than that of sole application of mNGF or cobamamide.
